2-Methoxyethyl-18-methoxycoronaridinate

2-Methoxyethyl-18-methoxycoronaridinate
Identifiers
PubChem CID	10070278;
ChemSpider	9212214 ;
Chemical and physical data
Formula	C24H32N2O4
Molar mass	412.530 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COCCOC(=O)C12CC(C4)CN(C2C4CCOC)CCc5c1c3ccccc35;
	InChI InChI=1S/C24H32N2O4/c1-28-10-8-17-13-16-14-24(23(27)30-12-11-29-2)21-19(7-9-26(15-16)22(17)24)18-5-3-4-6-20(18)25-21/h3-6,16-17,22,25H,7-15H2,1-2H3/t16-,17+,22+,24-/m1/s1 ; Key:OLFXZBDPKBSIPG-JIQZGXBJSA-N ;
	(verify)

(−)-2-Methoxyethyl-18-methoxycoronaridinate (ME-18-MC) is a second generation synthetic derivative of ibogaine developed by the research team led by the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont.^[1] In animal studies it has shown similar efficacy to the related compound 18-methoxycoronaridine (18-MC) at reducing self-administration of morphine and methamphetamine but with higher potency by weight, showing anti-addictive effects at the equivalent of half the minimum effective dose of 18-MC. Similarly to 18-MC itself, ME-18-MC acts primarily as a selective α₃β₄ nicotinic acetylcholine antagonist, although it has a slightly stronger effect than 18-MC as an NMDA antagonist, and its effects on opioid receptors are weaker than those of 18-MC at all except the kappa opioid receptor, at which it has slightly higher affinity than 18-MC.^[2]^[3]

References

^ US 6211360, Glick SD, Kuehne ME, "Ibogamine congeners", issued 3 April 2001, assigned to University of Vermont
^ Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, et al. (June 2003). "Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents". Journal of Medicinal Chemistry. 46 (13): 2716–30. doi:10.1021/jm020562o. PMID 12801235.
^ Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. PMID 15178360.

Zdroj:https://en.wikipedia.org?pojem=2-Methoxyethyl-18-methoxycoronaridinate
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] US 6211360, Glick SD, Kuehne ME, "Ibogamine congeners", issued 3 April 2001, assigned to University of Vermont

[2] Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, et al. (June 2003). "Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents". Journal of Medicinal Chemistry. 46 (13): 2716–30. doi:10.1021/jm020562o. PMID 12801235.

[3] Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration". European Journal of Pharmacology. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. PMID 15178360.

[1]

[2]

[3]

Identifiers

PubChem CID	10070278
ChemSpider	9212214^Y
Chemical and physical data
Formula	C₂₄H₃₂N₂O₄
Molar mass	412.530 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COCCOC(=O)C12CC(C4)CN(C2C4CCOC)CCc5c1c3ccccc35
InChI InChI=1S/C24H32N2O4/c1-28-10-8-17-13-16-14-24(23(27)30-12-11-29-2)21-19(7-9-26(15-16)22(17)24)18-5-3-4-6-20(18)25-21/h3-6,16-17,22,25H,7-15H2,1-2H3/t16-,17+,22+,24-/m1/s1^Y Key:OLFXZBDPKBSIPG-JIQZGXBJSA-N^Y
(verify)

See also

References